1 min read

Webinar | Strategies for Solving the Challenges of an Extraordinary Natural History Study

Navigating the Patient Experience When Pivoting to a Virtual Model Mid-Study

 

On-Demand Webinar

shutterstock_360398336_Woman Working From Home_Blog_opt1200Completing a natural history study for ultra-rare diseases can be critical to understanding the disease and its progression. The data from the natural history can be essential to informing the design and outcome selection of an interventional study. We explore the challenges of designing and running an extraordinary complex natural history study - with both retrospective and prospective data – which then had to pivot to virtual patient visits mid-way through the data collection process.

 


 

Our experts will share their experience, successes, and lessons learned on:

  • The need for and challenges of a Natural History study of Canavan Disease
  • Case Study: Strategies for addressing challenges of a unique study design
  • Pivoting to a virtual & in-person hybrid model during COVID-19

Watch Now:

FierceBio Webinar post play button


 


 

Meet the Speakers

 

Rachel Smith_bw_150x150

Rachel Smith

Portfolio Director, Veristat

Rachel has worked in clinical research for over 10 years working across all clinical phases (I-IV) with a focus on complex advanced therapy trials. She’s worked closely with innovative biopharma across different therapeutic areas. Rachel is currently the Portfolio Director of global cell and gene therapy programs, and the lead for the Veristat Global Cell and Gene Center of Excellence. She has a BSc (Hons) Biochemistry from the University of Warwick, is a Registered Member of the Institute of Clinical Research and has been published in the European Journal of Drug Metabolism and Pharmacokinetics and Lambert Academic publishing.

 

Kara Langer_HeadshotKara Langer

Senior Project Manager, Veristat

Kara is a clinical operations professional with 13 years’ experience, specializing in rare disease, gene therapy, COVID-19, and Oncology. Prior to Veristat, Kara held several roles at Covance before becoming a Project Manager. Kara is currently a Senior Project Manager at Veristat, dedicated to promoting subject safety, generating high-quality data, and maximizing study efficiency. She has a Bachelor of Science from the University of Wisconsin-Madison in Natural Sciences-Genetics and Anthropology

 


Learn More

 

Share This Event:

   

1 min read

Fierce Biotech Summit 2024

Meet Veristat in Boston at the Fierce Biotech Summit Conference | September 30 - October 1 in Boston, Massachusetts

We...

4 min read

Unique Challenges in Recruiting Patients for Rare Indication Pediatric Studies: Overcoming Difficulties through a Site and CRO Perspective

Don't miss Veristat’s plenary presentation at the World Orphan Drug Congress (WODC), Barcelona, Thursday, October 24th...